A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned.

Published on Jul 19, 2021in American Journal of Transplantation7.338
· DOI :10.1111/AJT.16742
Daan Kremer4
Estimated H-index: 4
(UMCG: University Medical Center Groningen),
Tobias T Pieters2
Estimated H-index: 2
+ 6 AuthorsBas W.M. van Balkom29
Estimated H-index: 29
Sources
Abstract
Kidney transplant recipients (KTR) may be at increased risk of adverse COVID-19 outcomes, due to prevalent comorbidities and immunosuppressed status. Given the global differences in COVID-19 policies and treatments, robust assessment of all evidence is necessary to evaluate the clinical course of COVID-19 in KTR. Studies on mortality and acute kidney injury (AKI) in KTR in the World Health Organization COVID-19 database were systematically reviewed. We selected studies published between March 2020 and January 18th 2021 including at least five KTR with COVID-19. Random-effects meta-analyses were performed to calculate overall proportions, including 95% confidence intervals (95%CI). Subgroup analyses were performed on time of submission, geographical region, sex, age, time after transplantation, comorbidities and treatments. We included 74 studies with 5,559 KTR with COVID-19 (64.0% males, mean age 58.2 years, mean 73 months after transplantation) in total. The risk of mortality, 23% (95%CI: 21%-27%), and AKI, 50% (95%CI: 44%-56%), is high among KTR with COVID-19, regardless of sex, age and comorbidities, underlining the call to accelerate vaccination programs for KTR. Given the suboptimal reporting across the identified studies, we urge researchers to consistently report anthropometrics, kidney function at baseline and discharge, (changes in) immunosuppressive therapy, AKI, and renal outcome among KTR.
References29
Newest
#1Bilgin Osmanodja (Humboldt University of Berlin)H-Index: 1
#1Bilgin Osmanodja (Humboldt University of Berlin)
Last. Klemens Budde (Humboldt University of Berlin)H-Index: 83
view all 5 authors...
1 CitationsSource
#1David A. Asch (Leonard Davis Institute of Health Economics)H-Index: 86
#2Natalie E. Sheils (UnitedHealth Group)H-Index: 8
Last. Jalpa A. Doshi (Leonard Davis Institute of Health Economics)H-Index: 43
view all 7 authors...
Importance: It is unknown how much the mortality of patients with coronavirus disease 2019 (COVID-19) depends on the hospital that cares for them, and whether COVID-19 hospital mortality rates are improving. Objective: To identify variation in COVID-19 mortality rates and how those rates have changed over the first months of the pandemic. Design, Setting, and Participants: This cohort study assessed 38 517 adults who were admitted with COVID-19 to 955 US hospitals from January 1, 2020, to June...
57 CitationsSource
#1Ozgur Akin Oto (Istanbul University)H-Index: 7
#2Savas Ozturk (UHSA: University of Health Sciences Antigua)H-Index: 13
Last. Alaattin Yildiz (Istanbul University)H-Index: 30
view all 25 authors...
BACKGROUND: We aimed to present the demographic characteristics, clinical presentation, and outcomes of our multicenter cohort of adult KTx recipients with COVID-19. METHODS: We conducted a multicenter, retrospective study using data of patients hospitalized for COVID-19 collected from 34 centers in Turkey. Demographic characteristics, clinical findings, laboratory parameters (hemogram, CRP, AST, ALT, LDH, and ferritin) at admission and follow-up, and treatment strategies were reviewed. Predicto...
4 CitationsSource
#1James Nugent (Yale University)H-Index: 1
#2Abinet Aklilu (Yale University)H-Index: 1
Last. Dennis G. Moledina (Yale University)H-Index: 14
view all 11 authors...
Importance Acute kidney injury (AKI) occurs in up to half of patients hospitalized with coronavirus disease 2019 (COVID-19). The longitudinal effects of COVID-19–associated AKI on kidney function remain unknown. Objective To compare the rate of change in estimated glomerular filtration rate (eGFR) after hospital discharge between patients with and without COVID-19 who experienced in-hospital AKI. Design, Setting, and Participants A retrospective cohort study was conducted at 5 hospitals in Conne...
14 CitationsSource
#1Simon JonesH-Index: 106
#2Neil MasonH-Index: 1
Last. Leora I. HorwitzH-Index: 47
view all 6 authors...
Early reports showed high mortality from coronavirus disease 2019 (COVID-19). Mortality rates have recently been lower; however, patients are also now younger, with fewer comorbidities. We explored 28-day mortality for patients hospitalized for COVID-19 in England over a 5-month period, adjusting for a range of potentially mitigating variables, including sociodemographics and comorbidities. Among 102,610 hospitalizations, crude mortality decreased from 33.4% (95% CI, 32.9-34.0) in March 2020 to ...
5 CitationsSource
#1Nathalie Chavarot (University of Paris)H-Index: 6
#2Juliette Gueguen (University of Paris)H-Index: 3
Last. Anne Scemla (Necker-Enfants Malades Hospital)H-Index: 19
view all 29 authors...
Higher rates of severe COVID-19 have been reported in kidney transplant recipients (KTRs) compared to non-transplant patients. We aimed to determine if poorer outcomes were specifically related to chronic immunosuppression or underlying comorbidities. We used a 1:1 propensity score-matching method to compare survival and severe disease-free survival (defined as death and/or need for intensive care unit (ICU)) incidence in hospitalized KTRs and non-transplant control patients between 26 February ...
12 CitationsSource
#1Lili Chan (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 11
#2Kumardeep Chaudhary (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 27
Last. Girish N. Nadkarni (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 34
view all 32 authors...
Background Early reports indicate that AKI is common among patients with coronavirus disease 2019 (COVID-19) and associated with worse outcomes. However, AKI among hospitalized patients with COVID-19 in the United States is not well described. Methods This retrospective, observational study involved a review of data from electronic health records of patients aged ≥18 years with laboratory-confirmed COVID-19 admitted to the Mount Sinai Health System from February 27 to May 30, 2020. We describe t...
112 CitationsSource
#1Savas Ozturk (UHSA: University of Health Sciences Antigua)H-Index: 13
#2Kenan Turgutalp (Mersin University)H-Index: 9
Last. Kenan Ates (Ankara University)H-Index: 20
view all 71 authors...
BACKGROUND: Chronic kidney disease (CKD) and immunosuppression, such as in renal transplantation (RT), stand as one of the established potential risk factors for severe coronavirus disease 2019 (COVID-19). Case morbidity and mortality rates for any type of infection have always been much higher in CKD, haemodialysis (HD) and RT patients than in the general population. A large study comparing COVID-19 outcome in moderate to advanced CKD (Stages 3-5), HD and RT patients with a control group of pat...
22 CitationsSource
#1Kitty J Jager (PHRI: Public Health Research Institute)H-Index: 29
#1Kitty J. Jager (PHRI: Public Health Research Institute)H-Index: 66
Last. Ziad A. Massy (French Institute of Health and Medical Research)H-Index: 73
view all 21 authors...
The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompa...
93 CitationsSource
#1Shruti Gupta (Harvard University)H-Index: 14
#1Shruti Gupta (Harvard University)H-Index: 5
Last. Stop-Covid InvestigatorsH-Index: 1
view all 34 authors...
Importance The US is currently an epicenter of the coronavirus disease 2019 (COVID-19) pandemic, yet few national data are available on patient characteristics, treatment, and outcomes of critical illness from COVID-19. Objectives To assess factors associated with death and to examine interhospital variation in treatment and outcomes for patients with COVID-19. Design, Setting, and Participants This multicenter cohort study assessed 2215 adults with laboratory-confirmed COVID-19 who were admitte...
280 CitationsSource
Cited By0
Newest